{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:59:05Z","timestamp":1767855545644,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"21-22","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00508-025-02529-3","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T10:08:11Z","timestamp":1744366091000},"page":"702-706","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High lymphocyte count and bleeding risk in patients with chronic lymphocytic leukemia treated with Bruton\u2019s tyrosine kinase inhibitors"],"prefix":"10.1007","volume":"137","author":[{"given":"Ivan","family":"Kre\u010dak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna","family":"Kvinta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Paladin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aron","family":"Grube\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Stani\u0107 Dami\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neven","family":"Franji\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josipa","family":"Budimir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josipa Antonija","family":"Ba\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davor","family":"Galu\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zinaida","family":"Peri\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Skelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"18","key":"2529_CR1","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1182\/bloodadvances.2022007938","volume":"6","author":"FT Awan","year":"2022","unstructured":"Awan\u00a0FT, Addison\u00a0D, Alfraih\u00a0F, et\u00a0al. International consensus statement on the management of cardiovascular risk of Bruton\u2019s tyrosine kinase inhibitors in CLL. Blood Adv. 2022;6(18):5516\u201325.","journal-title":"Blood Adv"},{"issue":"6","key":"2529_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/MBC.0000000000000749","volume":"29","author":"C Aguilar","year":"2018","unstructured":"Aguilar\u00a0C. Ibrutinib-related bleeding: pathogenesis, clinical implications and management. Blood Coagul Fibrinolysis. 2018;29(6):481\u20137.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2529_CR3","unstructured":"Piper L. Evobrutinib fails to improve response rate in refractory RA patients. Med Matters. 2020;."},{"issue":"25","key":"2529_CR4","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","volume":"380","author":"X Montalban","year":"2019","unstructured":"Montalban\u00a0X, Arnold\u00a0DL, Weber\u00a0MS, et\u00a0al. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N\u00a0Engl J Med. 2019;380(25):2406\u201317.","journal-title":"N Engl J Med"},{"issue":"2","key":"2529_CR5","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/cts.13162","volume":"15","author":"TD Owens","year":"2022","unstructured":"Owens\u00a0TD, Smith\u00a0PF, Redfern\u00a0A, et\u00a0al. Phase\u00a01 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168). Clin Transl Sci. 2022;15(2):442\u201350.","journal-title":"Clin Transl Sci"},{"issue":"6","key":"2529_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","volume":"25","author":"JA Burger","year":"2019","unstructured":"Burger\u00a0JA. Bruton Tyrosine kinase inhibitors: present and future. Cancer\u00a0J. 2019;25(6):386\u201393.","journal-title":"Cancer J"},{"issue":"25","key":"2529_CR7","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek\u00a0M, Cheson\u00a0BD, Catovsky\u00a0D, et\u00a0al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745\u201360.","journal-title":"Blood"},{"issue":"2","key":"2529_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","volume":"46","author":"KR Rai","year":"1975","unstructured":"Rai\u00a0KR, Sawitsky\u00a0A, Cronkite\u00a0EP, Chanana\u00a0AD, Levy\u00a0RN, Pasternack\u00a0BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219\u201334.","journal-title":"Blood"},{"issue":"3","key":"2529_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2141.1981.tb07243.x","volume":"49","author":"B Jaksic","year":"1981","unstructured":"Jaksic\u00a0B, Vitale\u00a0B. Total tumour mass score (TTM): a\u00a0new parameter in chronic lymphocyte leukaemia. Br J Haematol. 1981;49(3):405\u201313.","journal-title":"Br J Haematol"},{"issue":"5","key":"2529_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson\u00a0ME, Pompei\u00a0P, Ales\u00a0KL, MacKenzie\u00a0CR. A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J\u00a0Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"key":"2529_CR11","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/j.1532-5415.2008.01935.x","volume":"56","author":"F Salvi","year":"2008","unstructured":"Salvi\u00a0F, Miller\u00a0MD, Grilli\u00a0A, et\u00a0al. A\u00a0manual of guidelines to score the modified Cumulative Illness Rating Scale and its validation in acute hospitalized elderly patients. J\u00a0Am Geriatr Soc. 2008;56:1926\u201331.","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"2529_CR12","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","volume":"123","author":"JA Woyach","year":"2014","unstructured":"Woyach\u00a0JA, Smucker\u00a0K, Smith\u00a0LL, Lozanski\u00a0A, Zhong\u00a0Y, Ruppert\u00a0AS, et\u00a0al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a\u00a0suboptimal response to therapy. Blood. 2014;123(12):1810\u20137.","journal-title":"Blood"},{"issue":"11","key":"2529_CR13","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/leu.2014.122","volume":"28","author":"SE Herman","year":"2014","unstructured":"Herman\u00a0SE, Niemann\u00a0CU, Farooqui\u00a0M, Jones\u00a0J, Mustafa\u00a0RZ, Lipsky\u00a0A, et\u00a0al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a\u00a0phase\u00a0II study. Leukemia. 2014;28(11):2188\u201396.","journal-title":"Leukemia"},{"issue":"Supplement\u00a01","key":"2529_CR14","doi-asserted-by":"publisher","first-page":"4645","DOI":"10.1182\/blood-2023-174767","volume":"142","author":"G Follows","year":"2023","unstructured":"Follows\u00a0G, Ferrajoli\u00a0A, Byrd\u00a0JC, Shaw\u00a0B, Nozaki\u00a0K, Stewart\u00a0K, et\u00a0al. Elevate-TN: impact of first-year dose modifications in patients with treatment-naive chronic lymphocytic leukemia treated with Acalabrutinib. Blood. 2023;142(Supplement\u00a01):4645.","journal-title":"Blood"},{"issue":"22","key":"2529_CR15","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1182\/blood.2019896688","volume":"133","author":"IE Ahn","year":"2019","unstructured":"Ahn\u00a0IE, Basumallik\u00a0N, Tian\u00a0X, Soto\u00a0S, Wiestner\u00a0A. Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL. Blood. 2019;133(22):2452\u20135.","journal-title":"Blood"},{"issue":"3","key":"2529_CR16","doi-asserted-by":"publisher","first-page":"899","DOI":"10.4049\/jimmunol.142.3.899","volume":"142","author":"E Abraham","year":"1989","unstructured":"Abraham\u00a0E, Freitas\u00a0AA. Hemorrhage produces abnormalities in lymphocyte function and lymphokine generation. J\u00a0Immunol. 1989;142(3):899\u2013906.","journal-title":"J Immunol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02529-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-025-02529-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02529-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:23:03Z","timestamp":1762417383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-025-02529-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":16,"journal-issue":{"issue":"21-22","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2529"],"URL":"https:\/\/doi.org\/10.1007\/s00508-025-02529-3","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"2 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.\u00a0Kre\u010dak, B.\u00a0Kvinta, M.\u00a0Paladin, A.\u00a0Grube\u0161i\u0107, M.\u00a0Stani\u0107\u00a0Dami\u0107, N.\u00a0Franji\u0107, J.\u00a0Budimir, J.A.\u00a0Ba\u010di\u0107, D.\u00a0Galu\u0161i\u0107, Z.\u00a0Peri\u0107 and M.\u00a0Skelin declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}